Mandatory notification of trade - exercise of employee share options

Lysaker, April 27, 2015 – Exercise of employee share options in PCI Biotech Holding ASA ("the Company").

1. Participants in the Company's share option program have on April 27th 2015 exercised a total number of 174 000 options at a strike price of NOK 4.78.

Following the exercise, the Board of Directors, pursuant to authorisation granted by the Company's Annual General Meeting May 13th 2014, has decided to increase the Company's share capital by NOK 522 000 by issuing 174 000 new shares, of par value NOK 3.00. Subsequent to the transaction the Company's share capital is NOK 44 701 170 divided into 14 900 390 shares. The capital increase will result in gross proceeds of NOK 831 720.

2. Options exercised April 27th 2015
The primary insider and CEO, Per Walday, has exercised 60 000 options in the Company, corresponding to 60 000 shares at a strike price of NOK 4.78.

Other employees have exercised a total of 114 000 options, corresponding to 114 000 shares at a strike price of NOK 4.78.

3. Transfer of rights
On April 27th 2015, the primary insider, Per Walday CEO, has transferred 60 000 rights to receive shares resulting from the exercise of options to a third party. The sales amount will be finally determined on the basis of the price subsequently obtained by the third party when selling the shares in the market. Still, primary insiders cannot be held liable for losses incurred by the third party if the shares are later sold below the strike price. Final compensation for the transferred rights will be reported to Oslo Axess when known.

Other employees transferred a total of 90 000 out of 114 000 rights to receive shares resulting from the exercise of options to a third party.

4. Purchase of shares
On April 27th 2015, the primary insider, Per Walday CEO, has entered into an agreement to use the whole compensation, net of tax, mentioned in item 3 to purchase shares. When known, the final number of shares, along with the compensation, will be reported to Oslo Axess.

The other employees have also entered into agreements to use the whole compensation, net of tax, mentioned in item 3 to purchase shares.

5. New Holding
After exercising options, the primary insider, Per Walday CEO, holds a total of 126 000 unexercised options in the Company, corresponding to 80 000 unexercised options at a strike price of NOK 14.07,16 000 unexercised options at a strike price of NOK 27.38 and 30 000 unexercised options at a strike price of NOK 27.54. Prior to the abovementioned transactions, Per Walday CEO, holds 22 872 shares in the Company and the final new share holding will be reported to Oslo Axess when known.

For further information, please contact
Ronny Skuggedal,CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.